{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:01:29Z","timestamp":1794002489565,"version":"4.8.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG-1807-31964 and RG-1508-05912"],"award-info":[{"award-number":["RG-1807-31964 and RG-1508-05912"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NS112727 and AI144004"],"award-info":[{"award-number":["NS112727 and AI144004"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Henry Ford Hospital Internal Grant","award":["A10270 and A30967"],"award-info":[{"award-number":["A10270 and A30967"]}],"id":[{"id":"https:\/\/ror.org\/0193sb042","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple sclerosis (MS) is an inflammatory demyelinating disease of the nervous system that primarily affects young adults. Although the exact etiology of the disease remains obscure, it is clear that alterations in the metabolome contribute to this process. As such, defining a reliable and disease-specific metabolome has tremendous potential as a diagnostic and therapeutic strategy for MS. Here, we provide an overview of studies aimed at identifying the role of metabolomics in MS. These offer new insights into disease pathophysiology and the contributions of metabolic pathways to this process, identify unique markers indicative of treatment responses, and demonstrate the therapeutic effects of drug-like metabolites in cellular and animal models of MS. By and large, the commonly perturbed pathways in MS and its preclinical model include lipid metabolism involving alpha-linoleic acid pathway, nucleotide metabolism, amino acid metabolism, tricarboxylic acid cycle,\n                    <jats:sc>d<\/jats:sc>\n                    -ornithine and\n                    <jats:sc>d<\/jats:sc>\n                    -arginine pathways with collective role in signaling and energy supply. The metabolomics studies suggest that metabolic profiling of MS patient samples may uncover biomarkers that will advance our understanding of disease pathogenesis and progression, reduce delays and mistakes in diagnosis, monitor the course of disease, and detect better drug targets, all of which will improve early therapeutic interventions and improve evaluation of response to these treatments.\n                  <\/jats:p>","DOI":"10.1007\/s00018-020-03733-2","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T03:03:26Z","timestamp":1610679806000},"page":"3181-3203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-1959","authenticated-orcid":false,"given":"Insha","family":"Zahoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrani","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"2","key":"3733_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple Sclerosis. N Engl J Med 378(2):169\u2013180","journal-title":"N Engl J Med"},{"issue":"6","key":"3733_CR2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.msard.2014.09.002","volume":"3","author":"K O'Connell","year":"2014","unstructured":"O\u2019Connell K et al (2014) Economic costs associated with an MS relapse. Mult Scler Relat Disord 3(6):678\u2013683","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"3733_CR3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L (2017) Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13(1):25\u201336","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"3733_CR4","first-page":"948","volume":"40","author":"BK Tsang","year":"2011","unstructured":"Tsang BK, Macdonell R (2011) Multiple sclerosis- diagnosis, management and prognosis. Aust Fam Physician 40(12):948\u2013955","journal-title":"Aust Fam Physician"},{"key":"3733_CR5","first-page":"285245","volume":"2014","author":"SS Duffy","year":"2014","unstructured":"Duffy SS, Lees JG, Moalem-Taylor G (2014) The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Int 2014:285245","journal-title":"Mult Scler Int"},{"issue":"1","key":"3733_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04143.x","volume":"162","author":"JM Fletcher","year":"2010","unstructured":"Fletcher JM et al (2010) T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162(1):1\u201311","journal-title":"Clin Exp Immunol"},{"key":"3733_CR7","doi-asserted-by":"crossref","unstructured":"Popescu BF, Pirko I, Lucchinetti CF (2013) Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) 19(4 Multiple Sclerosis): 901\u2013921.","DOI":"10.1212\/01.CON.0000433291.23091.65"},{"issue":"1","key":"3733_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","volume":"93","author":"R Dutta","year":"2011","unstructured":"Dutta R, Trapp BD (2011) Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93(1):1\u201312","journal-title":"Prog Neurobiol"},{"key":"3733_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/400_2009_21","volume":"51","author":"MS Weber","year":"2010","unstructured":"Weber MS, Hemmer B (2010) Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis. Results Probl Cell Differ 51:115\u2013126","journal-title":"Results Probl Cell Differ"},{"issue":"2","key":"3733_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbadis.2010.06.009","volume":"1812","author":"MS Weber","year":"2011","unstructured":"Weber MS, Hemmer B, Cepok S (2011) The role of antibodies in multiple sclerosis. Biochim Biophys Acta 1812(2):239\u2013245","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"3733_CR11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.autrev.2005.03.005","volume":"4","author":"T Ziemssen","year":"2005","unstructured":"Ziemssen T, Ziemssen F (2005) The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev 4(7):460\u2013467","journal-title":"Autoimmun Rev"},{"issue":"3","key":"3733_CR12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278\u2013286","journal-title":"Neurology"},{"issue":"6\u20137","key":"3733_CR13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0035-3787(07)90474-9","volume":"163","author":"H Lassmann","year":"2007","unstructured":"Lassmann H (2007) Experimental models of multiple sclerosis. Rev Neurol (Paris) 163(6\u20137):651\u2013655","journal-title":"Rev Neurol (Paris)"},{"issue":"3","key":"3733_CR14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pneurobio.2010.06.005","volume":"92","author":"E Mix","year":"2010","unstructured":"Mix E et al (2010) Animal models of multiple sclerosis\u2013potentials and limitations. Prog Neurobiol 92(3):386\u2013404","journal-title":"Prog Neurobiol"},{"key":"3733_CR15","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 9:3116","journal-title":"Front Immunol"},{"issue":"3","key":"3733_CR16","doi-asserted-by":"crossref","first-page":"a028936","DOI":"10.1101\/cshperspect.a028936","volume":"8","author":"H Lassmann","year":"2018","unstructured":"Lassmann H (2018) Multiple SCLEROSIS PATHOLOGY. Cold Spring Harb Perspect Med 8(3):a028936","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3733_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08796-4","author":"I Zahoor","year":"2020","unstructured":"Zahoor I, Giri S (2020) Specialized pro-resolving lipid mediators: emerging therapeutic candidates for multiple sclerosis. Clin Rev Allergy Immunol. https:\/\/doi.org\/10.1007\/s12016-020-08796-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"3733_CR18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.msard.2019.03.006","volume":"31","author":"SL Andersen","year":"2019","unstructured":"Andersen SL et al (2019) Metabolome-based signature of disease pathology in MS. Mult Scler Relat Disord 31:12\u201321","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"3733_CR19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1352458515622827","volume":"22","author":"P Bhargava","year":"2016","unstructured":"Bhargava P, Calabresi PA (2016) Metabolomics in multiple sclerosis. Mult Scler 22(4):451\u2013460","journal-title":"Mult Scler"},{"key":"3733_CR20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2019.07.029","volume":"416","author":"G Lee","year":"2019","unstructured":"Lee G et al (2019) Identification of altered metabolic pathways during disease progression in EAE Mice via metabolomics and lipidomics. Neuroscience 416:74\u201387","journal-title":"Neuroscience"},{"issue":"2","key":"3733_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.nrl.0000254705.39956.34","volume":"13","author":"LA Rolak","year":"2007","unstructured":"Rolak LA, Fleming JO (2007) The differential diagnosis of multiple sclerosis. Neurologist 13(2):57\u201372","journal-title":"Neurologist"},{"issue":"24","key":"3733_CR22","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1212\/WNL.0b013e318259e2e2","volume":"78","author":"RA Rudick","year":"2012","unstructured":"Rudick RA, Miller AE (2012) Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis. Neurology 78(24):1904\u20131906","journal-title":"Neurology"},{"key":"3733_CR23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fneur.2019.00466","volume":"10","author":"MI Gaitan","year":"2019","unstructured":"Gaitan MI, Correale J (2019) Multiple Sclerosis Misdiagnosis: A Persistent Problem to Solve. Front Neurol 10:466","journal-title":"Front Neurol"},{"key":"3733_CR24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1749-6632.2011.06272.x","volume":"1247","author":"S Saidha","year":"2012","unstructured":"Saidha S, Eckstein C, Calabresi PA (2012) New and emerging disease modifying therapies for multiple sclerosis. Ann N Y Acad Sci 1247:117\u2013137","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3733_CR25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1039\/B906712B","volume":"40","author":"WB Dunn","year":"2011","unstructured":"Dunn WB et al (2011) Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 40(1):387\u2013426","journal-title":"Chem Soc Rev"},{"key":"3733_CR26","doi-asserted-by":"crossref","unstructured":"Nalbantoglu, S., Metabolomics: Basic Principles and Strategies, Molecular Medicine, Sinem Nalbantoglu and Hakima Amri. IntechOpen 2019. Available from:https:\/\/www.intechopen.com\/books\/molecular-medicine\/metabolomics-basic-principles-and-strategies.","DOI":"10.5772\/intechopen.88563"},{"issue":"5","key":"3733_CR27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/14737159.8.5.617","volume":"8","author":"GA Gowda","year":"2008","unstructured":"Gowda GA et al (2008) Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 8(5):617\u2013633","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"3733_CR28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/pme.13.8","volume":"10","author":"J Sun","year":"2013","unstructured":"Sun J, Beger RD, Schnackenberg LK (2013) Metabolomics as a tool for personalizing medicine: 2012 update. Per Med 10(2):149\u2013161","journal-title":"Per Med"},{"key":"3733_CR29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpba.2013.09.025","volume":"93","author":"IF Duarte","year":"2014","unstructured":"Duarte IF, Diaz SO, Gil AM (2014) NMR metabolomics of human blood and urine in disease research. J Pharm Biomed Anal 93:17\u201326","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"3733_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11882-014-0445-5","volume":"14","author":"R Scrivo","year":"2014","unstructured":"Scrivo R et al (2014) Metabolomics approach in allergic and rheumatic diseases. Curr Allergy Asthma Rep 14(6):445","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"3733_CR31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.semnephrol.2010.07.007","volume":"30","author":"JH Wang","year":"2010","unstructured":"Wang JH, Byun J, Pennathur S (2010) Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol 30(5):500\u2013511","journal-title":"Semin Nephrol"},{"issue":"4","key":"3733_CR32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.molcel.2015.04.021","volume":"58","author":"N Zamboni","year":"2015","unstructured":"Zamboni N, Saghatelian A, Patti GJ (2015) Defining the metabolome: size, flux, and regulation. Mol Cell 58(4):699\u2013706","journal-title":"Mol Cell"},{"key":"3733_CR33","doi-asserted-by":"crossref","unstructured":"Hy\u00f6tyl\u00e4inen, T. and S.e. Wiedmer, Chromatographic Methods in Metabolomics. United Kingdom: The Royal Society of Chemistry, 2013.","DOI":"10.1039\/9781849737272"},{"issue":"4","key":"3733_CR34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nbt.4101","volume":"36","author":"C Guijas","year":"2018","unstructured":"Guijas C et al (2018) Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol 36(4):316\u2013320","journal-title":"Nat Biotechnol"},{"issue":"12","key":"3733_CR35","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/j.1600-6143.2005.01119.x","volume":"5","author":"DS Wishart","year":"2005","unstructured":"Wishart DS (2005) Metabolomics: the principles and potential applications to transplantation. Am J Transplant 5(12):2814\u20132820","journal-title":"Am J Transplant"},{"issue":"5","key":"3733_CR36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/1352458519876020","volume":"26","author":"P Bhargava","year":"2020","unstructured":"Bhargava P, Anthony DC (2020) Metabolomics in multiple sclerosis disease course and progression. Mult Scler 26(5):591\u2013598","journal-title":"Mult Scler"},{"issue":"19","key":"3733_CR37","doi-asserted-by":"crossref","first-page":"e95302","DOI":"10.1172\/jci.insight.95302","volume":"2","author":"P Bhargava","year":"2017","unstructured":"Bhargava P et al (2017) Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight 2(19):e95302","journal-title":"JCI Insight"},{"issue":"2","key":"3733_CR38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.410320205","volume":"32","author":"H Bruhn","year":"1992","unstructured":"Bruhn H et al (1992) Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 32(2):140\u2013150","journal-title":"Ann Neurol"},{"issue":"7","key":"3733_CR39","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1371\/journal.pone.0000595","volume":"2","author":"NW Lutz","year":"2007","unstructured":"Lutz NW et al (2007) Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid. PLoS ONE 2(7):e595","journal-title":"PLoS ONE"},{"issue":"52","key":"3733_CR40","doi-asserted-by":"crossref","first-page":"30697","DOI":"10.1074\/jbc.M115.679068","volume":"290","author":"LM Poisson","year":"2015","unstructured":"Poisson LM et al (2015) Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis. J Biol Chem 290(52):30697\u201330712","journal-title":"J Biol Chem"},{"issue":"10","key":"3733_CR41","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1177\/1352458513516528","volume":"20","author":"SN Reinke","year":"2014","unstructured":"Reinke SN et al (2014) Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis. Mult Scler 20(10):1396\u20131400","journal-title":"Mult Scler"},{"issue":"1","key":"3733_CR42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbrc.2006.12.169","volume":"354","author":"NW Lutz","year":"2007","unstructured":"Lutz NW et al (2007) A branched-chain organic acid linked to multiple sclerosis: first identification by NMR spectroscopy of CSF. Biochem Biophys Res Commun 354(1):160\u2013164","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"3733_CR43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nbd.2009.02.019","volume":"35","author":"MP Quinones","year":"2009","unstructured":"Quinones MP, Kaddurah-Daouk R (2009) Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 35(2):165\u2013176","journal-title":"Neurobiol Dis"},{"issue":"2","key":"3733_CR44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchromb.2008.05.001","volume":"871","author":"DS Wishart","year":"2008","unstructured":"Wishart DS et al (2008) The human cerebrospinal fluid metabolome. J Chromatogr B Analyt Technol Biomed Life Sci 871(2):164\u2013173","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"3733_CR45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100047922","volume":"20","author":"J Lynch","year":"1993","unstructured":"Lynch J et al (1993) Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. Can J Neurol Sci 20(3):194\u2013198","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"3733_CR46","first-page":"623","volume":"319","author":"F Nicoli","year":"1996","unstructured":"Nicoli F et al (1996) Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. C R Acad Sci III 319(7):623\u2013631","journal-title":"C R Acad Sci III"},{"issue":"12","key":"3733_CR47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0022-510X(96)00224-9","volume":"144","author":"IL Simone","year":"1996","unstructured":"Simone IL et al (1996) High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sci 144(12):182\u2013190","journal-title":"J Neurol Sci"},{"issue":"1","key":"3733_CR48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0404.1997.tb00060.x","volume":"95","author":"J Aasly","year":"1997","unstructured":"Aasly J et al (1997) Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis. Acta Neurol Scand 95(1):9\u201312","journal-title":"Acta Neurol Scand"},{"issue":"1\u20132","key":"3733_CR49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jns.2008.07.032","volume":"275","author":"WT Regenold","year":"2008","unstructured":"Regenold WT et al (2008) Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci 275(1\u20132):106\u2013112","journal-title":"J Neurol Sci"},{"issue":"2","key":"3733_CR50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/nbm.1428","volume":"23","author":"AJ Sinclair","year":"2010","unstructured":"Sinclair AJ et al (2010) NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases\u2014a diagnostic tool? NMR Biomed 23(2):123\u2013132","journal-title":"NMR Biomed"},{"issue":"4","key":"3733_CR51","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1471-4159.2012.07934.x","volume":"123","author":"H Gonzalo","year":"2012","unstructured":"Gonzalo H et al (2012) Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism. J Neurochem 123(4):622\u2013634","journal-title":"J Neurochem"},{"issue":"6","key":"3733_CR52","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1039\/C4MB00700J","volume":"11","author":"D Pieragostino","year":"2015","unstructured":"Pieragostino D et al (2015) An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis. Mol Biosyst 11(6):1563\u20131572","journal-title":"Mol Biosyst"},{"issue":"7","key":"3733_CR53","doi-asserted-by":"crossref","first-page":"e0181758","DOI":"10.1371\/journal.pone.0181758","volume":"12","author":"HH Kim","year":"2017","unstructured":"Kim HH et al (2017) Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. PLoS ONE 12(7):e0181758","journal-title":"PLoS ONE"},{"issue":"16","key":"3733_CR54","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.7150\/thno.26249","volume":"8","author":"S Herman","year":"2018","unstructured":"Herman S et al (2018) Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. Theranostics 8(16):4477\u20134490","journal-title":"Theranostics"},{"issue":"2","key":"3733_CR55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/cells8020084","volume":"8","author":"S Herman","year":"2019","unstructured":"Herman S et al (2019) Biochemical differences in cerebrospinal fluid between secondary progressive and relapsing(-)remitting multiple sclerosis. Cells 8(2):84","journal-title":"Cells"},{"issue":"1","key":"3733_CR56","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1038\/s41598-019-47906-x","volume":"9","author":"L Nogueras","year":"2019","unstructured":"Nogueras L et al (2019) Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis. Sci Rep 9(1):11313","journal-title":"Sci Rep"},{"issue":"1","key":"3733_CR57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12031-019-01336-6","volume":"69","author":"A Podlecka-Pietowska","year":"2019","unstructured":"Podlecka-Pietowska A et al (2019) Altered cerebrospinal fluid concentrations of hydrophobic and hydrophilic compounds in early stages of multiple sclerosis-metabolic profile analyses. J Mol Neurosci 69(1):94\u2013105","journal-title":"J Mol Neurosci"},{"issue":"2","key":"3733_CR58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11306-020-1648-5","volume":"16","author":"H Carlsson","year":"2020","unstructured":"Carlsson H et al (2020) Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry. Metabolomics 16(2):26","journal-title":"Metabolomics"},{"issue":"3","key":"3733_CR59","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/jcm9030863","volume":"9","author":"F Murgia","year":"2020","unstructured":"Murgia F et al (2020) Multi-platform characterization of cerebrospinal fluid and serum metabolome of patients affected by relapsing-remitting and primary progressive multiple sclerosis. J Clin Med 9(3):863","journal-title":"J Clin Med"},{"issue":"1","key":"3733_CR60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","volume":"13","author":"M Comabella","year":"2014","unstructured":"Comabella M, Montalban X (2014) Body fluid biomarkers in multiple sclerosis. Lancet Neurol 13(1):113\u2013126","journal-title":"Lancet Neurol"},{"issue":"1","key":"3733_CR61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2015.06.015","volume":"161","author":"WJ Housley","year":"2015","unstructured":"Housley WJ, Pitt D, Hafler DA (2015) Biomarkers in multiple sclerosis. Clin Immunol 161(1):51\u201358","journal-title":"Clin Immunol"},{"issue":"8","key":"3733_CR62","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s00415-012-6413-x","volume":"259","author":"BL Wright","year":"2012","unstructured":"Wright BL, Lai JT, Sinclair AJ (2012) Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 259(8):1530\u20131545","journal-title":"J Neurol"},{"issue":"2","key":"3733_CR63","first-page":"455","volume":"27","author":"JH Simon","year":"2006","unstructured":"Simon JH et al (2006) Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 27(2):455\u2013461","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"3733_CR64","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/SHK.0000000000000406","volume":"44","author":"KA Stringer","year":"2015","unstructured":"Stringer KA et al (2015) Whole blood reveals more metabolic detail of the human metabolome than serum as measured by 1H-NMR spectroscopy: implications for sepsis metabolomics. Shock 44(3):200\u2013208","journal-title":"Shock"},{"issue":"12","key":"3733_CR65","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.jprot.2011.06.023","volume":"74","author":"P Del Boccio","year":"2011","unstructured":"Del Boccio P et al (2011) Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteomics 74(12):2826\u20132836","journal-title":"J Proteomics"},{"key":"3733_CR66","first-page":"167156","volume":"2011","author":"B Tavazzi","year":"2011","unstructured":"Tavazzi B et al (2011) Serum metabolic profile in multiple sclerosis patients. Mult Scler Int 2011:167156","journal-title":"Mult Scler Int"},{"issue":"2","key":"3733_CR67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/mrc.3915","volume":"51","author":"M Mehrpour","year":"2013","unstructured":"Mehrpour M et al (2013) A metabonomics investigation of multiple sclerosis by nuclear magnetic resonance. Magn Reson Chem 51(2):102\u2013109","journal-title":"Magn Reson Chem"},{"key":"3733_CR68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.biocel.2017.07.004","volume":"93","author":"S Poddighe","year":"2017","unstructured":"Poddighe S et al (2017) Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. Int J Biochem Cell Biol 93:148\u2013155","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"3733_CR69","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1212\/NXI.0000000000000185","volume":"3","author":"E Cocco","year":"2016","unstructured":"Cocco E et al (2016) (1)H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(1):e185","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"3733_CR70","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1212\/NXI.0000000000000321","volume":"4","author":"P Villoslada","year":"2017","unstructured":"Villoslada P et al (2017) Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 4(2):e321","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"3733_CR71","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1039\/C9MD00253G","volume":"10","author":"MF Kasakin","year":"2019","unstructured":"Kasakin MF et al (2019) Targeted metabolomics approach for identification of relapsing-remitting multiple sclerosis markers and evaluation of diagnostic models. Medchemcomm 10(10):1803\u20131809","journal-title":"Medchemcomm"},{"key":"3733_CR72","doi-asserted-by":"crossref","first-page":"146589","DOI":"10.1016\/j.brainres.2019.146589","volume":"1732","author":"DA Sylvestre","year":"2020","unstructured":"Sylvestre DA et al (2020) Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain. Brain Res 1732:146589","journal-title":"Brain Res"},{"issue":"5","key":"3733_CR73","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/1352458513504638","volume":"20","author":"FM Moussallieh","year":"2014","unstructured":"Moussallieh FM et al (2014) Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis. Mult Scler 20(5):558\u2013565","journal-title":"Mult Scler"},{"issue":"1","key":"3733_CR74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40478-017-0495-8","volume":"5","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M et al (2017) Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease. Acta Neuropathol Commun 5(1):95","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"3733_CR75","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1007\/s12035-016-0257-9","volume":"54","author":"G Lazzarino","year":"2017","unstructured":"Lazzarino G et al (2017) Serum compounds of energy metabolism impairment are related to disability, disease course and neuroimaging in multiple sclerosis. Mol Neurobiol 54(9):7520\u20137533","journal-title":"Mol Neurobiol"},{"key":"3733_CR76","doi-asserted-by":"crossref","first-page":"41473","DOI":"10.1038\/srep41473","volume":"7","author":"CK Lim","year":"2017","unstructured":"Lim CK et al (2017) Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep 7:41473","journal-title":"Sci Rep"},{"issue":"10","key":"3733_CR77","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/acn3.637","volume":"5","author":"B Nourbakhsh","year":"2018","unstructured":"Nourbakhsh B et al (2018) Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Ann Clin Transl Neurol 5(10):1211\u20131221","journal-title":"Ann Clin Transl Neurol"},{"issue":"17","key":"3733_CR78","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1212\/WNL.0000000000000905","volume":"83","author":"AM Dickens","year":"2014","unstructured":"Dickens AM et al (2014) A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology 83(17):1492\u20131499","journal-title":"Neurology"},{"key":"3733_CR79","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fnhum.2018.00226","volume":"12","author":"D Stoessel","year":"2018","unstructured":"Stoessel D et al (2018) Metabolomic profiles for primary progressive multiple sclerosis stratification and disease course monitoring. Front Hum Neurosci 12:226","journal-title":"Front Hum Neurosci"},{"issue":"6","key":"3733_CR80","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.gpb.2015.08.005","volume":"13","author":"M An","year":"2015","unstructured":"An M, Gao Y (2015) Urinary biomarkers of brain diseases. Genom Proteom Bioinform 13(6):345\u2013354","journal-title":"Genom Proteom Bioinform"},{"issue":"12","key":"3733_CR81","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s11427-013-4574-1","volume":"56","author":"Y Gao","year":"2013","unstructured":"Gao Y (2013) Urine-an untapped goldmine for biomarker discovery? Sci China Life Sci 56(12):1145\u20131146","journal-title":"Sci China Life Sci"},{"issue":"1\u20132","key":"3733_CR82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-510X(03)00080-7","volume":"212","author":"BA Hart","year":"2003","unstructured":"Hart BA et al (2003) 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci 212(1\u20132):21\u201330","journal-title":"J Neurol Sci"},{"issue":"6","key":"3733_CR83","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mrm.1910290605","volume":"29","author":"RE Brenner","year":"1993","unstructured":"Brenner RE et al (1993) The proton NMR spectrum in acute EAE: the significance of the change in the Cho: Cr ratio. Magn Reson Med 29(6):737\u2013745","journal-title":"Magn Reson Med"},{"issue":"6","key":"3733_CR84","first-page":"409","volume":"48","author":"C Gay","year":"1991","unstructured":"Gay C et al (1991) N-acetylaspartic aciduria. Clinical, biological and physiopathological study. Arch Fr Pediatr 48(6):409\u2013413","journal-title":"Arch Fr Pediatr"},{"issue":"6","key":"3733_CR85","first-page":"1535","volume":"13","author":"RI Grossman","year":"1992","unstructured":"Grossman RI et al (1992) MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 13(6):1535\u20131543","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"3733_CR86","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mrm.1910320603","volume":"32","author":"NE Preece","year":"1994","unstructured":"Preece NE et al (1994) Experimental encephalomyelitis modulates inositol and taurine in the spinal cord of Biozzi mice. Magn Reson Med 32(6):692\u2013697","journal-title":"Magn Reson Med"},{"issue":"2","key":"3733_CR87","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/acs.jproteome.5b01111","volume":"15","author":"T Gebregiworgis","year":"2016","unstructured":"Gebregiworgis T et al (2016) A urinary metabolic signature for multiple sclerosis and neuromyelitis optica. J Proteome Res 15(2):659\u2013666","journal-title":"J Proteome Res"},{"key":"3733_CR88","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fimmu.2020.00157","volume":"11","author":"L Gaetani","year":"2020","unstructured":"Gaetani L et al (2020) Host and microbial tryptophan metabolic profiling in multiple sclerosis. Front Immunol 11:157","journal-title":"Front Immunol"},{"issue":"7","key":"3733_CR89","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(08)70137-6","volume":"7","author":"R Bakshi","year":"2008","unstructured":"Bakshi R et al (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7):615\u2013625","journal-title":"Lancet Neurol"},{"key":"3733_CR90","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.neuroimage.2013.05.125","volume":"82","author":"LK Vingara","year":"2013","unstructured":"Vingara LK et al (2013) Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. Neuroimage 82:586\u2013594","journal-title":"Neuroimage"},{"key":"3733_CR91","doi-asserted-by":"crossref","unstructured":"Cicalini, I., et al. Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid. Int J Mol Sci, 2019. 20(6).","DOI":"10.3390\/ijms20061265"},{"issue":"2","key":"3733_CR92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","volume":"133","author":"H Lassmann","year":"2017","unstructured":"Lassmann H, Bradl M (2017) Multiple sclerosis: experimental models and reality. Acta Neuropathol 133(2):223\u2013244","journal-title":"Acta Neuropathol"},{"key":"3733_CR93","first-page":"10","volume":"4","author":"A Mangalam","year":"2013","unstructured":"Mangalam A et al (2013) Profile of circulatory metabolites in a relapsing-remitting animal model of multiple sclerosis using global metabolomics. J Clin Cell Immunol 4:10","journal-title":"J Clin Cell Immunol"},{"issue":"2","key":"3733_CR94","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11481-018-9815-4","volume":"14","author":"J Singh","year":"2019","unstructured":"Singh J et al (2019) Urinary and plasma metabolomics identify the distinct metabolic profile of disease state in chronic mouse model of multiple sclerosis. J Neuroimmune Pharmacol 14(2):241\u2013250","journal-title":"J Neuroimmune Pharmacol"},{"issue":"4","key":"3733_CR95","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","volume":"164","author":"CS Constantinescu","year":"2011","unstructured":"Constantinescu CS et al (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164(4):1079\u20131106","journal-title":"Br J Pharmacol"},{"issue":"3","key":"3733_CR96","first-page":"278","volume":"45","author":"AM Brown","year":"1981","unstructured":"Brown AM, McFarlin DE (1981) Relapsing experimental allergic encephalomyelitis in the SJL\/J mouse. Lab Invest 45(3):278\u2013284","journal-title":"Lab Invest"},{"issue":"5966","key":"3733_CR97","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/309356a0","volume":"309","author":"F Mokhtarian","year":"1984","unstructured":"Mokhtarian F, McFarlin DE, Raine CS (1984) Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 309(5966):356\u2013358","journal-title":"Nature"},{"issue":"6035","key":"3733_CR98","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/317355a0","volume":"317","author":"S Zamvil","year":"1985","unstructured":"Zamvil S et al (1985) T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317(6035):355\u2013358","journal-title":"Nature"},{"issue":"6","key":"3733_CR99","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jnr.24224","volume":"96","author":"I Bjelobaba","year":"2018","unstructured":"Bjelobaba I et al (2018) Animal models of multiple sclerosis: Focus on experimental autoimmune encephalomyelitis. J Neurosci Res 96(6):1021\u20131042","journal-title":"J Neurosci Res"},{"key":"3733_CR100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2016.08.013","volume":"304","author":"AE Lovett-Racke","year":"2017","unstructured":"Lovett-Racke AE (2017) Contribution of EAE to understanding and treating multiple sclerosis. J Neuroimmunol 304:40\u201342","journal-title":"J Neuroimmunol"},{"issue":"2","key":"3733_CR101","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11306-011-0306-3","volume":"8","author":"MJ Noga","year":"2012","unstructured":"Noga MJ et al (2012) Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis. Metabolomics 8(2):253\u2013263","journal-title":"Metabolomics"},{"issue":"3","key":"3733_CR102","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11481-015-9622-0","volume":"10","author":"AM Dickens","year":"2015","unstructured":"Dickens AM et al (2015) NMR-based metabolomics separates the distinct stages of disease in a chronic relapsing model of multiple sclerosis. J Neuroimmune Pharmacol 10(3):435\u2013444","journal-title":"J Neuroimmune Pharmacol"},{"key":"3733_CR103","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2017.11.018","volume":"314","author":"S Battini","year":"2018","unstructured":"Battini S et al (2018) Metabolomics approaches in experimental allergic encephalomyelitis. J Neuroimmunol 314:94\u2013100","journal-title":"J Neuroimmunol"},{"key":"3733_CR104","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1471-2105-12-254","volume":"12","author":"L Blanchet","year":"2011","unstructured":"Blanchet L et al (2011) Fusion of metabolomics and proteomics data for biomarkers discovery: case study on the experimental autoimmune encephalomyelitis. BMC Bioinformatics 12:254","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"3733_CR105","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00216-012-5871-4","volume":"403","author":"A Smolinska","year":"2012","unstructured":"Smolinska A et al (2012) Simultaneous analysis of plasma and CSF by NMR and hierarchical models fusion. Anal Bioanal Chem 403(4):947\u2013959","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"3733_CR106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08820138209050718","volume":"11","author":"SL Abreu","year":"1982","unstructured":"Abreu SL (1982) Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun 11(1):1\u20137","journal-title":"Immunol Commun"},{"issue":"4","key":"3733_CR107","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","volume":"43","author":"DW Paty","year":"1993","unstructured":"Paty DW, Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43(4):662\u2013667","journal-title":"Neurology"},{"key":"3733_CR108","doi-asserted-by":"crossref","unstructured":"Johnson, K.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995. 45(7): 1268\u20131276.","DOI":"10.1212\/WNL.45.7.1268"},{"issue":"4","key":"3733_CR109","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/eji.1830010406","volume":"1","author":"D Teitelbaum","year":"1971","unstructured":"Teitelbaum D et al (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1(4):242\u2013248","journal-title":"Eur J Immunol"},{"issue":"9","key":"3733_CR110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910","journal-title":"N Engl J Med"},{"issue":"6364","key":"3733_CR111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock TA et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356(6364):63\u201366","journal-title":"Nature"},{"issue":"2","key":"3733_CR112","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10865-007-9139-y","volume":"31","author":"RL Aupperle","year":"2008","unstructured":"Aupperle RL et al (2008) Omega-3 fatty acids and multiple sclerosis: relationship to depression. J Behav Med 31(2):127\u2013135","journal-title":"J Behav Med"},{"issue":"4","key":"3733_CR113","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ajcn\/50.4.801","volume":"50","author":"SC Cunnane","year":"1989","unstructured":"Cunnane SC et al (1989) Essential fatty acid and lipid profiles in plasma and erythrocytes in patients with multiple sclerosis. Am J Clin Nutr 50(4):801\u2013806","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"3733_CR114","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/jnnp.33.4.506","volume":"33","author":"S Gul","year":"1970","unstructured":"Gul S et al (1970) Fatty acid composition of phospholipids from platelets and erythrocytes in multiple sclerosis. J Neurol Neurosurg Psychiatry 33(4):506\u2013510","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"3733_CR115","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1073\/pnas.86.12.4720","volume":"86","author":"RT Holman","year":"1989","unstructured":"Holman RT, Johnson SB, Kokmen E (1989) Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis. Proc Natl Acad Sci USA 86(12):4720\u20134724","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"3733_CR116","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0404.1990.tb01586.x","volume":"82","author":"S Nightingale","year":"1990","unstructured":"Nightingale S et al (1990) Red blood cell and adipose tissue fatty acids in mild inactive multiple sclerosis. Acta Neurol Scand 82(1):43\u201350","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"3733_CR117","doi-asserted-by":"crossref","first-page":"e55859","DOI":"10.1371\/journal.pone.0055859","volume":"8","author":"H Pruss","year":"2013","unstructured":"Pruss H et al (2013) Proresolution lipid mediators in multiple sclerosis\u2014differential, disease severity-dependent synthesis - a clinical pilot trial. PLoS ONE 8(2):e55859","journal-title":"PLoS ONE"},{"issue":"8","key":"3733_CR118","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3324\/haematol.2019.219519","volume":"105","author":"G Kooij","year":"2020","unstructured":"Kooij G et al (2020) Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica 105(8):2056\u20132070","journal-title":"Haematologica"},{"key":"3733_CR119","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpba.2015.06.028","volume":"115","author":"C Zhao","year":"2015","unstructured":"Zhao C et al (2015) Metabolomic analysis revealed glycylglycine accumulation in astrocytes after methionine enkephalin administration exhibiting neuron protective effects. J Pharm Biomed Anal 115:48\u201354","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"3733_CR120","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/ng.3695","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang J et al (2016) Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet 48(11):1396\u20131406","journal-title":"Nat Genet"},{"issue":"2","key":"3733_CR121","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cct.2014.10.004","volume":"39","author":"P Bhargava","year":"2014","unstructured":"Bhargava P et al (2014) The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 39(2):288\u2013293","journal-title":"Contemp Clin Trials"},{"issue":"7707","key":"3733_CR122","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41586-018-0119-x","volume":"557","author":"V Rothhammer","year":"2018","unstructured":"Rothhammer V et al (2018) Microglial control of astrocytes in response to microbial metabolites. Nature 557(7707):724\u2013728","journal-title":"Nature"},{"issue":"6","key":"3733_CR123","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.4106","volume":"22","author":"V Rothhammer","year":"2016","unstructured":"Rothhammer V et al (2016) Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22(6):586\u2013597","journal-title":"Nat Med"},{"issue":"1","key":"3733_CR124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/acn3.676","volume":"6","author":"P Bhargava","year":"2019","unstructured":"Bhargava P et al (2019) Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. Ann Clin Transl Neurol 6(1):33\u201345","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"3733_CR125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s13311-019-00721-8","volume":"16","author":"L Lorefice","year":"2019","unstructured":"Lorefice L et al (2019) Assessing the metabolomic profile of multiple sclerosis patients treated with interferon beta 1a by (1)H-NMR spectroscopy. Neurotherapeutics 16(3):797\u2013807","journal-title":"Neurotherapeutics"},{"issue":"5","key":"3733_CR126","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.stem.2012.10.002","volume":"11","author":"CD Folmes","year":"2012","unstructured":"Folmes CD et al (2012) Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 11(5):596\u2013606","journal-title":"Cell Stem Cell"},{"issue":"4","key":"3733_CR127","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrm3772","volume":"15","author":"K Ito","year":"2014","unstructured":"Ito K, Suda T (2014) Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol 15(4):243\u2013256","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3733_CR128","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cmet.2016.07.002","volume":"24","author":"T TeSlaa","year":"2016","unstructured":"TeSlaa T et al (2016) Alpha-ketoglutarate accelerates the initial differentiation of primed human pluripotent stem cells. Cell Metab 24(3):485\u2013493","journal-title":"Cell Metab"},{"issue":"6","key":"3733_CR129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nchembio.364","volume":"6","author":"O Yanes","year":"2010","unstructured":"Yanes O et al (2010) Metabolic oxidation regulates embryonic stem cell differentiation. Nat Chem Biol 6(6):411\u2013417","journal-title":"Nat Chem Biol"},{"issue":"1","key":"3733_CR130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nchembio.2517","volume":"14","author":"BA Beyer","year":"2018","unstructured":"Beyer BA et al (2018) Metabolomics-based discovery of a metabolite that enhances oligodendrocyte maturation. Nat Chem Biol 14(1):22\u201328","journal-title":"Nat Chem Biol"},{"issue":"1","key":"3733_CR131","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","volume":"15","author":"S MahmoudianDehkordi","year":"2019","unstructured":"MahmoudianDehkordi S et al (2019) Altered bile acid profile associates with cognitive impairment in Alzheimer\u2019s disease-An emerging role for gut microbiome. Alzheimers Dement 15(1):76\u201392","journal-title":"Alzheimers Dement"},{"issue":"2","key":"3733_CR132","doi-asserted-by":"crossref","first-page":"E302","DOI":"10.1073\/pnas.1716032115","volume":"115","author":"N Itoh","year":"2018","unstructured":"Itoh N et al (2018) Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. Proc Natl Acad Sci USA 115(2):E302\u2013E309","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"3733_CR133","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1172\/JCI129401","volume":"130","author":"P Bhargava","year":"2020","unstructured":"Bhargava P et al (2020) Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. J Clin Invest 130(7):3467\u20133482","journal-title":"J Clin Invest"},{"issue":"1","key":"3733_CR134","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpbi.86","volume":"68","author":"J Chong","year":"2019","unstructured":"Chong J, Wishart DS, Xia J (2019) Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinformatics 68(1):86","journal-title":"Curr Protoc Bioinformatics"},{"issue":"4","key":"3733_CR135","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1021\/cb300673e","volume":"8","author":"T Gebregiworgis","year":"2013","unstructured":"Gebregiworgis T et al (2013) Potential of urinary metabolites for diagnosing multiple sclerosis. ACS Chem Biol 8(4):684\u2013690","journal-title":"ACS Chem Biol"},{"key":"3733_CR136","first-page":"205294","volume":"2017","author":"M Zhao","year":"2017","unstructured":"Zhao M et al (2017) Early urinary candidate biomarkers in a rat model of experimental autoimmune encephalomyelitis. bioRxiv 2017:205294","journal-title":"bioRxiv"},{"issue":"4","key":"3733_CR137","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1212\/01.WNL.0000046662.03894.C5","volume":"60","author":"A Bertolotto","year":"2003","unstructured":"Bertolotto A et al (2003) Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60(4):634\u2013639","journal-title":"Neurology"},{"issue":"22","key":"3733_CR138","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L et al (2017) Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology 89(22):2230\u20132237","journal-title":"Neurology"},{"issue":"9","key":"3733_CR139","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458511404271","volume":"17","author":"PS Sorensen","year":"2011","unstructured":"Sorensen PS et al (2011) Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 17(9):1074\u20131078","journal-title":"Mult Scler"},{"issue":"4","key":"3733_CR140","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/prca.201500083","volume":"10","author":"P Del Boccio","year":"2016","unstructured":"Del Boccio P et al (2016) Integration of metabolomics and proteomics in multiple sclerosis: from biomarkers discovery to personalized medicine. Proteomics Clin Appl 10(4):470\u2013484","journal-title":"Proteomics Clin Appl"},{"key":"3733_CR141","doi-asserted-by":"crossref","first-page":"12015","DOI":"10.1038\/ncomms12015","volume":"7","author":"S Jangi","year":"2016","unstructured":"Jangi S et al (2016) Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 7:12015","journal-title":"Nat Commun"},{"issue":"7612","key":"3733_CR142","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature18646","volume":"535","author":"HK Pedersen","year":"2016","unstructured":"Pedersen HK et al (2016) Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535(7612):376\u2013381","journal-title":"Nature"},{"issue":"6","key":"3733_CR143","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","volume":"20","author":"MM Rinschen","year":"2019","unstructured":"Rinschen MM et al (2019) Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol 20(6):353\u2013367","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-020-03733-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-020-03733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T08:35:23Z","timestamp":1724315723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-020-03733-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":143,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3733"],"URL":"https:\/\/doi.org\/10.1007\/s00018-020-03733-2","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No consent was required to prepare the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}